TY - JOUR
T1 - NCCN Guidelines Updates
T2 - Management of Metastatic Kidney Cancer
AU - Jonasch, Eric
N1 - Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2019/5/1
Y1 - 2019/5/1
N2 - The NCCN Guidelines for Kidney Cancer have undergone a major shift in the risk categorization used for designating "preferred" and "other recommended" or "useful under certain circumstances" first-line treatments. In the most recent version of the guidelines, "favorable risk" is now its own risk category and "intermediate risk" and "poor risk" are combined into one category. The treatment recommendations for clear cell renal cell carcinoma are continually revised and more new options are anticipated based on encouraging results from pivotal trials. In his presentation at the NCCN 2019 Annual Conference, Dr. Jonasch described these promising findings.
AB - The NCCN Guidelines for Kidney Cancer have undergone a major shift in the risk categorization used for designating "preferred" and "other recommended" or "useful under certain circumstances" first-line treatments. In the most recent version of the guidelines, "favorable risk" is now its own risk category and "intermediate risk" and "poor risk" are combined into one category. The treatment recommendations for clear cell renal cell carcinoma are continually revised and more new options are anticipated based on encouraging results from pivotal trials. In his presentation at the NCCN 2019 Annual Conference, Dr. Jonasch described these promising findings.
UR - http://www.scopus.com/inward/record.url?scp=85066493219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066493219&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2019.5008
DO - 10.6004/jnccn.2019.5008
M3 - Letter
C2 - 31117033
AN - SCOPUS:85066493219
SN - 1540-1405
VL - 17
SP - 587
EP - 589
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 55
ER -